Abstract
Targeted immunotherapies represent a major breakthrough in cancer treatment, offering precise and personalized approaches to combating malignancies. These therapies enhance the body’s immune system to recognize and eliminate cancer cells with minimal damage to normal tissues. Recent advances include immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and cancer vaccines. This article explores the mechanisms, clinical applications, challenges, and future directions of targeted immunotherapies in oncology.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.